Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it presented new preclinical efficacy data for its novel anti-cancer drug candidate, Supinoxin™ (RX-5902) at the American Society for Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium in San Francisco, California.
In a poster presentation entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Renal Cell Cancer,” Rexahn scientists detailed the results of several preclinical studies showing the antiproliferative effects of Supinoxin in various human renal cancer cell lines and xenograft renal cancer models.
In one study, Supinoxin was administered orally to mice once weekly for four weeks to assess its anti-tumor effects in a xenograft model of renal cell cancer. The results suggested that Supinoxin achieved clinically meaningful tumor growth inhibition of greater than 60%.
In a separate xenograft study, Supinoxin was administered orally to mice five days per week for 21 days (similar to the current dosing paradigm in the ongoing Phase I study). This study suggested that Supinoxin achieved dose-dependent tumor growth inhibition of greater than 60% and a partial clinical response in 60% of the animals and a complete response in 10% of the animals at a dose of 70 mg/kg.
“We are very pleased to see further evidence of the anti-cancer effects of Supinoxin in additional human cancer cell lines,” said Dr. Ely Benaim, Chief Medical Officer for Rexahn Pharmaceuticals. “Late last year Rexahn presented data at the San Antonio Breast Cancer Symposium showing potent tumor inhibition effects of Supinoxin in a well validated preclinical model of human triple negative breast cancer (TNBC) — a particularly aggressive form of breast cancer for which there is high unmet medical need. The additional information from the preclinical pharmacokinetic and pharmacodynamic studies, along with data from the ongoing Phase I clinical trial will inform our decision on the recommended dose for a Phase Ib/IIa proof-of-concept clinical study.” (Original Source)
Shares of Rexahn Pharmaceuticals closed yesterday at $0.33. RNN has a 1-year high of $0.95 and a 1-year low of $0.33. The stock’s 50-day moving average is $0.40 and its 200-day moving average is $0.50.
On the ratings front, Roth Capital analyst Joseph Pantginis maintained a Buy rating on RNN, with a price target of $3, in a report issued on November 6. The current price target implies an upside of 809.1% from current levels. According to TipRanks.com, Pantginis has a total average return of -11.6%, a 31.7% success rate, and is ranked #3578 out of 3594 analysts.
Rexahn Pharmaceuticals Inc is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs.